Pfizer Head of R&D Business Development-Asia Alex Fowkes On Developing R&D Strategies For Asia: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Pfizer Head of R&D Business Development-Asia Alex Fowkes sat down recently with PharmAsia News' Australia bureau to discuss Pfizer's research and business development strategies in Asia. Fowkes recently addressed a panel at the BioAsia conference in Singapore and discussed Pfizer's virtual networking approach to doing business in Asia, which offers more flexibility and creative approaches (PharmAsia News, May 8, 2008).
You may also be interested in...
Pfizer Forges New Research Partnership In China Aimed In Part At Fighting A Leading Cause Of Death
BEIJING - Still expanding globally after engineering the pharmaceutical world's most massive merger of the year, the titan-like Pfizer is partnering with the comparatively tiny contract research organization Crown Bioscience to develop new medicines aimed at fighting cancers that are prevalent in Asia, according to a leading Pfizer Asia executive
Pfizer Forges New Research Partnership In China Aimed In Part At Fighting A Leading Cause Of Death
BEIJING - Still expanding globally after engineering the pharmaceutical world's most massive merger of the year, the titan-like Pfizer is partnering with the comparatively tiny contract research organization Crown Bioscience to develop new medicines aimed at fighting cancers that are prevalent in Asia, according to a leading Pfizer Asia executive
Pfizer Forges Research Partnership In China Aimed At Fighting Cancers Prevalent In Asia
Scientists from Pfizer and Crown Bioscience join forces to research and develop novel treatments, including therapeutics to combat liver cancer, the second leading cause of cancer death in China.